Astra USA Sexual Harassment Suit Dismissed
- A suit brought by a former employee of Astra USA has been dismissed by a Massachusetts Superior Court judge, reports the Wall Street Journal. Part of the case was said to have come under a settlement agreement, which the employee had reached with the firm earlier this year.
The employee, Pamela Zortman, can amend her complaint within 10 days, the judge said, claiming that Astra violated terms of the settlement reached with her when it allegedly defamed her in speaking about the case in public. Ms Zortman reached a settlement of $100,000 relating to sexual harassment charges against Astra and former president Lars Bildman.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze